stockrow
Friday 6 November 2026
Export ALPS’s income statement to Excel — free account
Alps Group Inc.
ALPS Healthcare Biotechnology
Alps Group Inc.’s revenue for fiscal 2026 (year ended March 2026) was $4.9 million, up 44.1% from fiscal 2025.
- EPS
- −609.4%
- Free cash flow
- −26.5%
Quarter to September 2025, against a year earlier
0.33
0.02
+6.45%
Follow ALPS
Alert me
Alps Group Inc. (ALPS) P/E ratio
Alps Group Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 160× (March 2023) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|---|---|
| FY2026 | 0.0× | — |
| FY2025 | 0.0× | — |
| FY2024 | 144× | — |
Against its own ten years
Low 0.0×
High 160×
Ten-year median
0.0×
Current reading's percentile
66
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| KLRS Kalaris Therapeutics Inc. compare | n/m |
| HRTX Heron Therapeutics, Inc. compare | n/m |
| RNTX Rein Therapeutics Inc. compare | n/m |
| ELOX Senesco Technologies Inc. compare | n/m |
| ALPS Alps Group Inc. | n/m |
| INKT MiNK Therapeutics, Inc. compare | n/m |
| OSTX OS Therapies Incorporated compare | n/m |
| VRCA Verrica Pharmaceuticals Inc. compare | n/m |
| RNXT RenovoRx, Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)